Breaking Finance News

Wave Life Sciences Ltd (NASDAQ:WVE) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.

Boasting a price of $22.37, Wave Life Sciences Ltd (NASDAQ:WVE) traded 0.90% higher on the day. With the last stock price up 44.17% from the 200-day average, compared to the S&P 500 Index which has fallen -0.01% over the same period. WVE has registered a 50-day moving average of $21.90 and 200-day moving average of $17.83. 125,147 shares of the stock traded hands, up from ann avg. trading volume of 64,447

Zacks Investment Research has downgraded Wave Life Sciences Ltd(NASDAQ:WVE) to Sell in a report released 8/19/2016.

On Monday December 7 2015, Jefferies released a statement on Wave Life Sciences Ltd(NASDAQ:WVE) bumped the target price from $0.00 to $28.00 that indicated a possible upside of 0.00%.

See Chart Below:

Wave Life Sciences Ltd (NASDAQ:WVE)

Wave Life Sciences Ltd has a one-year low of $8.95 and a one-year high of $27.18. Wave Life Sciences Ltd’s total market value is currently $0.0.

Brief Synopsis About Wave Life Sciences Ltd (NASDAQ:WVE)

WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington’s disease, duchenne muscular dystrophy (DMD) and inflammatory bowel disease (IBD). In Huntington’s disease, it has programs that target HTT SNP-1 and HTT SNP-2; in DMD, it targets Exon 51, and in IBD, it targets SMAD7. It has selected lead product candidates in its programs targeting HTT SNP-1 and Exon 51. It has late-stage discovery programs in epidermolysis bullosa simplex, in which it targets KRT14 SNP-1 and KRT14 SNP-2, and in DMD, in which it is focused on an additional DMD target, and AcRIIb.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *